What is Zacks Research’s Forecast for Humana Q1 Earnings?

Humana Inc. (NYSE:HUM) – Equities researchers at Zacks Research lifted their Q1 2025 earnings per share estimates for shares of Humana in a research report issued on Tuesday, February 25th. Zacks Research analyst D. Chatterjee now expects that the insurance provider will post earnings per share of $9.91 for the quarter, up from their previous estimate of $6.37. The consensus estimate for Humana’s current full-year earnings is $16.47 per share. Zacks Research also issued estimates for Humana’s Q2 2025 earnings at $5.31 EPS, Q3 2025 earnings at $2.87 EPS, Q4 2025 earnings at ($1.85) EPS, Q2 2026 earnings at $4.29 EPS, Q4 2026 earnings at ($2.41) EPS and FY2026 earnings at $10.92 EPS.

Humana (NYSE:HUM) last released its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%.

Several other brokerages have also weighed in on HUM. TD Cowen increased their target price on Humana from $261.00 to $268.00 and gave the stock a “hold” rating in a research report on Monday, November 4th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $290.00 price target on shares of Humana in a research note on Wednesday, February 12th. Bank of America raised shares of Humana from an “underperform” rating to a “neutral” rating and lifted their price objective for the stock from $247.00 to $308.00 in a research note on Wednesday, November 6th. Barclays boosted their target price on Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 13th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $283.00 target price on shares of Humana in a research report on Wednesday, February 12th. Nineteen research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $285.68.

Humana Price Performance

Shares of NYSE:HUM opened at $261.49 on Friday. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. The firm has a 50-day simple moving average of $270.64 and a 200 day simple moving average of $287.87. The company has a market cap of $31.55 billion, a PE ratio of 26.28, a P/E/G ratio of 2.05 and a beta of 0.56. Humana has a fifty-two week low of $213.31 and a fifty-two week high of $406.46.

Institutional Trading of Humana

Institutional investors have recently modified their holdings of the company. AMF Tjanstepension AB increased its holdings in Humana by 166.8% in the 3rd quarter. AMF Tjanstepension AB now owns 40,051 shares of the insurance provider’s stock valued at $12,686,000 after buying an additional 25,041 shares during the period. Assenagon Asset Management S.A. boosted its position in shares of Humana by 12.7% during the 3rd quarter. Assenagon Asset Management S.A. now owns 4,090 shares of the insurance provider’s stock valued at $1,295,000 after acquiring an additional 461 shares in the last quarter. AustralianSuper Pty Ltd increased its stake in Humana by 35.2% in the third quarter. AustralianSuper Pty Ltd now owns 2,495 shares of the insurance provider’s stock valued at $790,000 after acquiring an additional 650 shares during the period. Creative Financial Designs Inc. ADV raised its position in Humana by 244.0% in the third quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock worth $27,000 after purchasing an additional 61 shares in the last quarter. Finally, CacheTech Inc. raised its position in Humana by 5.7% in the third quarter. CacheTech Inc. now owns 7,818 shares of the insurance provider’s stock worth $2,476,000 after purchasing an additional 422 shares in the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Insider Activity at Humana

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the company’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the transaction, the insider now owns 8,181 shares of the company’s stock, valued at $2,096,463.06. This represents a 31.16 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.32% of the stock is owned by corporate insiders.

Humana Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be given a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.35%. The ex-dividend date is Friday, March 28th. Humana’s dividend payout ratio is currently 35.58%.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.